James Wassil, an officer of Vaxcyte, Inc., filed a Form 144 notice of proposed sale on November 2, 2026, indicating his intent to sell 2,250 shares of Vaxcyte common stock through UBS Financial Services, Inc. on NASDAQ.

Key Highlights

  • Proposed sale: 2,250 shares of Vaxcyte, Inc. common stock with an aggregate market value of $139,230.00, according to the filing.
  • Filer: James Wassil (listed as "Wassil Jim" in filer fields), identified as an officer of Vaxcyte, Inc.
  • Acquisition: The 2,250 shares were acquired on November 2, 2026, via exercise of a stock option from the issuer, with cash payment on the same date.
  • Broker: UBS Financial Services, Inc., 11 Madison Ave, 4th Floor, New York, NY 10010 is named as broker for the proposed sale.
  • Shares outstanding: 148,805,278 shares of common stock outstanding, as reported in the filing.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of December 9, 2025.
  • Prior three-month sales: James Wassil sold a combined total of 28,692 shares in multiple transactions between August 3, 2026, and October 5, 2026, generating aggregate gross proceeds across those transactions as reported individually in the filing.

Wassil Proposes Rule 144 Sale Following Stock Option Exercise at Vaxcyte

According to the Form 144 filed on November 2, 2026, with the SEC, James Wassil, an officer of Vaxcyte, Inc. (NASDAQ:PCVX), proposed to sell 2,250 shares of the company's common stock. The filing lists the approximate sale date as November 2, 2026, with UBS Financial Services, Inc. acting as the executing broker on NASDAQ. The aggregate market value of the proposed sale is reported as $139,230.00.

The filing discloses that the 2,250 shares subject to the proposed sale were acquired on November 2, 2026, through the exercise of a stock option granted by the issuer, with full cash payment made on the same date. The notice was signed by UBS Financial Services Inc. as attorney-in-fact for James Wassil, and it references a Rule 10b5-1 written trading plan adopted on December 9, 2025.

In the section covering securities sold during the past three months, the filing lists six prior transactions by James Wassil: 2,250 shares sold on August 3, 2026, for gross proceeds of $121,194.45; 3,477 shares sold on September 1, 2026, for $212,352.66; 1,381 shares sold on September 4, 2026, for $84,462.51; 1,334 shares sold on September 9, 2026, for $79,400.61; 2,250 shares sold on October 1, 2026, for $127,512.45; and 18,000 shares sold on October 5, 2026, for $1,561,320.00. Vaxcyte, Inc. is headquartered at 825 Industrial Road, Suite 300, San Carlos, California 94070, and its SEC file number is 001-39323.

What Was Disclosed

James Wassil, an officer of Vaxcyte, Inc., filed a Form 144 on November 2, 2026, proposing to sell 2,250 shares of common stock with an aggregate market value of $139,230.00, acquired via stock option exercise on the same date under a 10b5-1 plan adopted December 9, 2025.